Partial Thromboplastin Time Concept

subject area of

• A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients with Advanced Solid Tumors  Academic Article
• A cohort study of coagulation parameters and the use of blood products in surgery of the thoracic and thoracoabdominal aorta  Academic Article
• A comparison of the anti thrombotic and haemorrhagic effects of low molecular weight heparin fractions: The influence of the method of preparation  Academic Article
• A non-anticoagulant synthetic pentasaccharide reduces inflammation in a murine model of kidney ischemia-reperfusion injury  Academic Article
• A novel congenital haemostatic defect: combined factor VII and factor XI deficiency.  Academic Article
• A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin  Academic Article
• A standard heparin nomogram for the management of heparin therapy  Academic Article
• ASH evidence-based guidelines: should asymptomatic patients with antiphospholipid antibodies receive primary prophylaxis to prevent thrombosis?  Academic Article
• Accumulation of radiolabelled platelets and fibrin on the carotid artery of rabbits after angioplasty: effects of heparin and dipyridamole  Academic Article
• Activated Partial Thromboplastin Time and Outcome After Thrombolytic Therapy for Acute Myocardial Infarction  Academic Article
• Activation of factor X and prothrombin in antithrombin-III depleted plasma: The effects of heparin  Academic Article
• Adjusted Subcutaneous Heparin or Continuous Intravenous Heparin in Patients with Acute Deep Vein Thrombosis  Academic Article
• Adjusted Subcutaneous Heparin versus Warfarin Sodium in the Long-Term Treatment of Venous Thrombosis  Academic Article
• Age-related differences in heparin response  Academic Article
• An Approach to Assigning In Vitro Potency to Unfractionated and Low Molecular Weight Heparins Based on the Inhibition of Prothrombin Activation and Catalysis of Thrombin Inhibition  Academic Article
• An important role for the activation peptide domain in controlling factor IX levels in the blood of haemophilia B mice  Conference Paper
• Anticoagulant and Antithrombin Effects of Intimatan, a Heparin Cofactor II Agonist  Academic Article
• Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls  Academic Article
• Antithrombotic Therapy in Neonates and Children  Academic Article
• Antithrombotic therapy in deep vein thrombosis and pulmonary embolism.  Academic Article
• Approaches to investigating common bleeding disorders: An evaluation of North American coagulation laboratory practices  Academic Article
• Autoimmune heparin-induced thrombocytopenia  Academic Article
• Basic coagulation tests as surrogates of dabigatran levels in a pre-operative setting: Analysis of five activated partial thromboplastin time reagents and thrombin time  Academic Article
• Coagulation Assays  Academic Article
• Coagulopathies in Patients After Transurethral Resection of the Prostate  Academic Article
• Coagulopathy in a patient with nephrotic syndrome  Academic Article
• Coagulopathy related to dilution and hypotension during massive transfusion  Academic Article
• Comparison Of The Relative Efficacy And Safety Of Low Molecular Weight Heparin And Unfractionated Heparin For The Treatment Of Venous Thrombosis  Conference Paper
• Comparison of Fixed-Dose Weight-Adjusted Unfractionated Heparin and Low-Molecular-Weight Heparin for Acute Treatment of Venous Thromboembolism  Academic Article
• Comparison of High-Dose with Low-Dose Subcutaneous Heparin to Prevent Left Ventricular Mural Thrombosis in Patients with Acute Transmural Anterior Myocardial Infarction  Academic Article
• Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the organization to assess strategies in acute ischemic syndromes (OASIS)-5 trial  Academic Article
• Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents  Academic Article
• Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers  Academic Article
• Complications of long-term anticoagulation  Academic Article
• Continuous Intravenous Heparin Compared with Intermittent Subcutaneous Heparin in the Initial Treatment of Proximal-Vein Thrombosis  Academic Article
• Critical Values in the Coagulation Laboratory Results of a Survey of the North American Specialized Coagulation Laboratory Association  Academic Article
• Dabigatran monitoring made simple?  Academic Article
• Decreased Concentrations of Heparinoids Are Required to Inhibit Thrombin Generation in Plasma from Newborns and Children Compared to Plasma from Adults due to Reduced Thrombin Potential  Academic Article
• Development of the human coagulation system in the full-term infant.  Academic Article
• Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation  Academic Article
• Different Intensities of Oral Anticoagulant Therapy in the Treatment of Proximal-Vein Thrombosis  Academic Article
• Discordance between the anti-Xa activity and the antithrombotic activity of an ultra-low molecular weight heparin fraction  Academic Article
• Effect of Dermatan Sulphate on Activated Partial Thromboplastin Time Determined with Different Reagents  Academic Article
• Effect of Warfarin on Activated Partial Thromboplastin Time in Patients Receiving Heparin  Academic Article
• Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure  Academic Article
• Effects on Thrombin Generation of Single Injections of Hirulog™ in Patients with Calf Vein Thrombosis  Academic Article
• Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non–Q-Wave Myocardial Infarction  Academic Article
• Establishing a Therapeutic Range for Heparin Therapy  Academic Article
• Evidence for a saturable mechanism of disappearance of standard heparin in rabbits  Academic Article
• Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis  Academic Article
• Factors XI and XII are low in subjects with liver disease  Academic Article
• Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists  Academic Article
• Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group.  Academic Article
• Further Studies on the Mechanisms for the Antithrombotic Effects of Sulfated Polysaccharides in Rabbits  Academic Article
• HD1, a thrombin- and prothrombin-binding DNA aptamer, inhibits thrombin generation by attenuating prothrombin activation and thrombin feedback reactions  Academic Article
• Hemorrhagic Complications of Anticoagulant Therapy  Academic Article
• Heparin Binding to Plasma Proteins, an Important Mechanism for Heparin Resistance  Academic Article
• Heparin Therapy in Pediatric Patients: A Prospective Cohort Study  Academic Article
• Heparin and Low-Molecular-Weight Heparin  Academic Article
• Heparin resistance in acute coronary syndromes  Academic Article
• Heparin-Induced Thrombocytopenia in Critically Ill Patients  Academic Article
• High prevalence of abnormal preoperative coagulation tests in patients with adolescent idiopathic scoliosis  Academic Article
• Hirudin causes more bleeding than heparin in a rabbit ear bleeding model  Academic Article
• How to use unfractionated heparin to treat neonatal thrombosis in clinical practice  Academic Article
• Hypersulfated Low Molecular Weight Heparin with Reduced Affinity for Antithrombin Acts as an Anticoagulant by Inhibiting Intrinsic Tenase and Prothrombinase  Academic Article
• In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation  Academic Article
• Inhibition of factor X, factor V and prothrombin activation by the bis(lactobionic acid amide) LW10082  Academic Article
• Initial treatment of venous thromboembolism  Academic Article
• Laboratory Investigations for Bleeding Disorders  Academic Article
• Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants  Academic Article
• Management of iliofemoral thrombosis in a pregnant patient with heparin resistance  Academic Article
• Measurement of the Activated Partial Thromboplastin Time from a Capillary (fingerstick) Sample of Whole Blood: A New Method for Monitoring Heparin Therapy  Academic Article
• Mechanism of Action and Monitoring of Anticoagulants  Academic Article
• Monitoring and reversal of direct oral anticoagulants  Academic Article
• Monitoring unfractionated heparin with the aPTT: Time for a fresh look  Academic Article
• Multicentric evaluation of heparinase on aPTT, thrombin clotting time and a new PT reagent based on recombinant human tissue factor  Academic Article
• NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank  Academic Article
• Non-biological factors in day to day variation of heparin requirements.  Academic Article
• Optimal Dosing of Subcutaneous Unfractionated Heparin for the Treatment of Deep Vein Thrombosis  Academic Article
• Optimal therapeutic level of heparin therapy in patients with venous thrombosis  Academic Article
• Pharmacokinetics of High-Dose Abetimus Sodium in Normal Subjects With Specific Assessment of Effect on Coagulation  Academic Article
• Pharmacological Actions of Sulodexide  Academic Article
• Pregnancy and Deep Vein Thrombosis  Academic Article
• Preparation and partial characterization of human plasma depleted of antithrombin-III by heparin-sepharose affinity chromatography  Academic Article
• Prevention of left ventricular mural thrombus  Academic Article
• Progressive, Fatal Thrombosis Associated With Heparin-Induced Thrombocytopenia After Cardiac Surgery Despite “Therapeutic” Anticoagulation With Argatroban: Potential Role for PTT and ACT Confounding  Academic Article
• Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial  Academic Article
• Recurrent Venous Thrombosis and Heparin Therapy  Academic Article
• Relationship between the antithrombotic and anticoagulant effects of low molecular weight heparin  Academic Article
• Relationship of Activated Partial Thromboplastin Time to Coronary Events and Bleeding in Patients With Acute Coronary Syndromes Who Receive Heparin  Academic Article
• Respective role of antithrombin III and heparin cofactor II in the in vitro anticoagulant effect of heparin and of various sulphated polysaccharides  Academic Article
• Reversal of direct oral anticoagulants: a practical approach  Academic Article
• Selective and Sustained Inhibition of Surface-bound Thrombin Activity by Intimatan/Heparin Cofactor II and Its Relevance to Assessing Systemic Anticoagulation In Vivo, Ex Vivo and In Vitro  Academic Article
• Suboptimal Monitoring and Dosing of Unfractionated Heparin in Comparative Studies with Low-Molecular-Weight Heparin  Academic Article
• Sustained and therapeutic delivery of factor IX in nude haemophilia B mice by encapsulated C2C12 myoblasts: concurrent tumourigenesis  Academic Article
• Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin.  Academic Article
• The APTT Response of Pregnant Plasma to Unfractionated Heparin  Academic Article
• The absence of `minor' risk factors for recurrent venous thromboembolism: a systematic review of negative predictive values and negative likelihood ratios  Academic Article
• The comparison of the pharmacokinetics of a low molecular weight heparin in the newborn and adult pig  Academic Article
• The disappearance of a low molecular weight heparin fraction (cy 216) differs from standard heparin in rabbits  Academic Article
• The effect of thrombin inhibitors on tissue plasminogen activator induced thrombolysis in a rat model.  Academic Article
• The factor VIII-independent activation of factor X by factors IXa and VII in plasma  Academic Article
• The incidence and impact of lupus anticoagulants among patients in the intensive care unit.  Academic Article
• The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor  Academic Article
• The rate of fibrinopeptide B release modulates the rate of clot formation: a study with an acquired inhibitor to fibrinopeptide B release  Academic Article
• The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin  Academic Article
• The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits.  Academic Article
• The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study.  Academic Article
• The thrombogenicity of prothrombin complex concentrates: I. The relationship between characteristics and thrombogenicity in rabbits  Academic Article
• Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes  Academic Article
• Thrombin generation in newborn plasma is critically dependent on the concentration of prothrombin.  Academic Article
• Thrombin generation, ProC(®)Global, prothrombin time and activated partial thromboplastin time in thawed plasma stored for seven days and after methylene blue/light pathogen inactivation.  Academic Article
• Unfractionated heparin dosing in young infants: clinical outcomes in a cohort monitored with anti-factor Xa levels  Academic Article
• Use of a Fixed Activated Partial Thromboplastin Time Ratio to Establish a Therapeutic Range for Unfractionated Heparin  Academic Article
• Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction: results of GUSTO-I. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.  Academic Article
• Utility of aPTT in monitoring unfractionated heparin in children  Academic Article
• α2-Macroglobulin Remains as Important as Antithrombin III for Thrombin Regulation in Cord Plasma in the Presence of Endothelial Cell Surfaces  Academic Article